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To the Editor, 
We read with interest the article entitled “Prevalence 
of bone mineral density testing and osteoporosis man-
agement following low- and high-energy fractures” by 
Angthong et al. in Vol. 47, No 5 (2013) of your journal.
[1] We congratulate them for their inspiring work. How-
ever, the study itself has some methodological draw-
backs, and contains false interpretations of results that 
lead to misunderstanding: 
1. Inclusion of both low- and high-energy fracture 
patients to test probability of DEXA examination ren-
ders the criteria inconsistent. In the literature, the inci-
dence of osteoporosis is much less likely in high-energy 
fractures.[2-4] Thus, DEXA testing probability by the 
orthopedic surgeons is very low. In addition, the study’s 
high-energy fracture group comprised only six patients, 
which also limits its power. 
2. The authors covered all low-energy fractures in the 
study, including ankle, calcaneus, proximal humerus, and 
tibial plato, all of which might have been complicated by 
other pathologies and secondary causes of osteoporosis.
[4,5] While deciding which patients are to be tested, litera-
ture-based guidelines should be used. Had patients with 
only hip or vertebral low-energy fractures been selected, 
the results would be better understood.
3. Another issue that attracted our attention is that 
all post-menopausal women, and men aged 50 and older, 
should be evaluated clinically for risk of osteoporosis in 
order to determine the need for BMD testing. However, 
DEXA scanning is not a prerequisite for initiating os-
teoporosis treatment in patients who sustain low-energy 
fractures in either their vertebra or hip, since a clinical 
diagnosis can often be made in at-risk individuals. BMD 
testing is recommended only to determine severity of the 
disease, and to assess the response or efficacy of an ap-
proved osteoporosis drug therapy for these patients.[4,5]
Osteoporosis is a silent disease until complicated 
by low-energy fractures.[5] We entirely agree with the 
authors’ statement that many patients are not receiving 
adequate information about prevention or appropriate 
testing to diagnose osteoporosis or osteoporosis risk.
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